SunOpta Inc (STKL)
NASDAQ:STKL
Top Page
SunOpta
(NASDAQ:STKL)
Select Model
Select Model
Rating:61Neutral
Price Target:
$7.00
▲(7.86% Upside)
Action:ReiteratedDate:04/03/26
The score is driven primarily by improving financial performance (profitability recovery and sharp debt reduction), supported by a constructive technical uptrend. These positives are tempered by a relatively high P/E and no dividend yield, plus remaining concerns around modest margins and free-cash-flow consistency.
Positive Factors
Balance-sheet deleveraging
Material reduction in leverage and a move to positive ROE materially lowers financial risk and interest burden, increasing strategic flexibility. Improved balance-sheet capacity supports capex, working capital, and resilience through demand or input-cost cycles over months.
Negative Factors
Modest and thin margins
Low operating and net margins leave limited buffer against input-cost inflation or pricing pressure, constraining free cash generation and reinvestment. Persistent modest margins make earnings sensitive to small volume or cost swings, limiting durable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet deleveraging
Material reduction in leverage and a move to positive ROE materially lowers financial risk and interest burden, increasing strategic flexibility. Improved balance-sheet capacity supports capex, working capital, and resilience through demand or input-cost cycles over months.
Read all positive factors
SunOpta (STKL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$766.96M
Dividend YieldN/A
Average Volume (3M)1.95M
Price to Earnings (P/E)27.8
Beta (1Y)1.24
Revenue Growth11.31%
EPS Growth99.83%
CountryUS
Employees1,248
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.06
Shares Outstanding118,358,570
10 Day Avg. Volume1,252,869
30 Day Avg. Volume1,947,470
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.35
Price to Sales (P/S)0.54
P/FCF Ratio20.61
Enterprise Value/Market Cap1.49
Enterprise Value/Revenue1.39
Enterprise Value/Gross Profit9.77
Enterprise Value/Ebitda14.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.21
Revenue Forecast (FY)$876.36M
SunOpta Business Overview & Revenue Model
Company Description
SunOpta Inc. manufactures and sells plant-based and fruit-based food and beverage products to retail customers, foodservice distributors, branded food companies, and food manufacturers worldwide. The company operates through two segments, Plant-Ba...
How the Company Makes Money
SunOpta primarily makes money by manufacturing plant-based beverages and related products for other companies, generating revenue from selling finished goods and providing associated production services. A key component of its model is co-manufact...
SunOpta Earnings Call Summary
Earnings Call Date:Nov 05, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Neutral
SunOpta demonstrated strong revenue growth and customer demand across key product categories, despite facing significant operational challenges and cost pressures. The company made strategic decisions to prioritize long-term value, which resulted in short-term inefficiencies and delayed margin improvements.Positive Updates
Exceptional Revenue Growth
Revenue increased 17% year-over-year, driven entirely by customer demand, marking 9 successive quarters of average 15% volume growth.
Negative Updates
Operational Challenges and Inefficiencies
The rapid volume growth led to inefficiencies, increased maintenance costs, overtime expenses, and higher waste, particularly exacerbated by wastewater limitations at the Midlothian facility.
Read all updates
Q3-2025 Updates
Positive
Negative
Exceptional Revenue Growth
Revenue increased 17% year-over-year, driven entirely by customer demand, marking 9 successive quarters of average 15% volume growth.
Read all positive updates
Company Guidance
During SunOpta's Third Quarter Fiscal 2025 Earnings Conference Call, the company reported a 17% revenue increase, surpassing their expectations and demonstrating robust growth trends. This surge was entirely driven by a 17% volume growth across their top six customers, marking nine consecutive quarters averaging 15% volume growth. Significant growth was observed in plant-based milk, broth, and tea categories. The company is addressing short-term operational challenges, including inefficiencies in their production schedule, equipment maintenance, and increased short-term costs, but remains confident in achieving long-term margin expansion by mid-2026. SunOpta plans to invest in an additional line of aseptic processing capacity at their Midlothian facility, anticipating completion by late 2026, to meet the accelerating demand. The company updated its full-year revenue outlook to $812-$816 million and expects adjusted EBITDA of $90-$92 million, with a leverage ratio target of 2.8x by year-end. Despite short-term challenges, SunOpta is optimistic about its strategic position and long-term growth trajectory.SunOpta Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
66
Positive
Cash Flow
57
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 817.72M | 723.73M | 626.73M | 591.39M | 496.45M |
| Gross Profit | 115.95M | 96.30M | 86.00M | 98.14M | 81.14M |
| EBITDA | 83.30M | 52.80M | 33.55M | 38.12M | 25.78M |
| Net Income | 15.77M | -17.39M | -178.79M | -6.43M | -1.17M |
Balance Sheet | |||||
| Total Assets | 694.66M | 668.53M | 667.15M | 855.85M | 755.12M |
| Cash, Cash Equivalents and Short-Term Investments | 169.00K | 1.55M | 306.00K | 679.00K | 227.00K |
| Total Debt | 372.15M | 392.68M | 378.03M | 395.31M | 275.83M |
| Total Liabilities | 508.64M | 504.88M | 510.83M | 536.64M | 450.13M |
| Stockholders Equity | 186.02M | 148.59M | 156.32M | 319.21M | 304.98M |
Cash Flow | |||||
| Free Cash Flow | 21.23M | 18.10M | -31.28M | -64.56M | -101.12M |
| Operating Cash Flow | 49.66M | 50.03M | 14.84M | 60.58M | -21.43M |
| Investing Cash Flow | -29.56M | -18.68M | 44.03M | -106.82M | -94.45M |
| Financing Cash Flow | -28.94M | -31.09M | -50.80M | 46.70M | 115.86M |
SunOpta Technical Analysis
Positive
6.49
Price Trends
6.24
Positive
5.09
Positive
5.51
Positive
Market Momentum
0.07
Positive
68.77
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STKL, the sentiment is Positive. The current price of 6.49 is above the 20-day moving average (MA) of 6.47, above the 50-day MA of 6.24, and above the 200-day MA of 5.51, indicating a bullish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 68.77 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STKL.
SunOpta Risk Analysis
SunOpta disclosed 40 risk factors in its most recent earnings report. SunOpta reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SunOpta Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $1.13B | 4.20 | 13.51% | ― | 8.33% | 47.71% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | $766.96M | 27.76 | 9.29% | ― | 11.31% | 99.83% | |
61 Neutral | $471.48M | 19.90 | 12.18% | ― | 6.62% | -7.85% | |
53 Neutral | $334.26M | -50.11 | 2.03% | ― | 5.88% | -68.62% | |
45 Neutral | $79.16M | -0.21 | -111.73% | ― | -10.13% | -532.32% |
* Consumer Defensive Sector Average
STKL
SunOpta
6.48
2.38
58.05%
NATR
Nature's Sunshine Products
26.93
14.82
122.38%
SENEA
Seneca Foods
167.32
83.36
99.29%
HAIN
Hain Celestial
0.87
-2.18
-71.48%
USNA
USANA Health
18.11
-6.38
-26.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.